Peptio

Peptides and cognitive function research

Research on peptides studied for memory, focus and neuroprotection, and how much of it reaches clinical endpoints.

Cognitive endpoints are hard to measure and easy to overstate. A change on one laboratory task is not the same as a change in how someone functions, and this hub keeps that distinction visible.

Peptides studied in this area

  • Dihexa

    PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, Hexanoyl-Tyr-Ile-Ahx-NH2, ATH-1001

    A synthetic angiotensin IV analogue with no human study found. Its mechanism paper was retracted in 2025; FDA lists it as a withdrawn compounding nomination.

    AnimalNo published human datacognition / safety regulation
  • Selank

    TKPRPGP, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TP-7, Selank acetate

    A seven-amino-acid tuftsin analogue. Its patient studies are small, Russian and without placebo; FDA lists it as a withdrawn compounding nomination.

    Case reportIn clinical trialscognition / safety regulation
  • Semax

    Semaks, ACTH(4-7)-Pro-Gly-Pro, ACTH(4-7)PGP, MEHFPGP, Met-Glu-His-Phe-Pro-Gly-Pro

    A seven-amino-acid ACTH fragment analogue that FDA reports is registered in Russia. Its human studies are small, mostly Russian, and not placebo-randomised.

    Case reportIn clinical trialscognition / safety regulation
  • Tesamorelin

    Egrifta, Egrifta SV, Egrifta WR, TH9507

    A growth hormone-releasing hormone analogue approved in the US for one use: excess abdominal fat in adults with HIV and lipodystrophy.

    MetaApproved for a medical indicationweight management / cognition

Further reading

Safety

Is selank legal? What regulators have said

No regulator document found approves selank. What FDA, Health Canada and New Zealand's Medsafe have said about selling, importing and holding it.

10 sources

Comparison

Semax vs Selank: what the evidence separates

Semax and Selank compared on what was measured: small Russian studies, no head-to-head clinical trial, one shared fMRI study and different FDA histories.

27 sources